Non-Small Cell Lung Cancer
Conditions
Interventions
Recurrence and metastasis group (MRD-positive):
Recurrence/metastasis-free group (MRD-negative):
Sponsors
Henan Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years, regardless of gender; 2. Patients with non-small cell lung cancer (Stage ?-?) confirmed by histology and/or cytology; 3. Patients diagnosed with non-small cell lung cancer eligible for radical surgical treatment; 4. Patients can provide residual formalin-fixed paraffin-embedded (FFPE) tumor tissue samples from the concurrent diagnosis and treatment process, or fresh tissue samples collected by the biospecimen bank, and cooperate with the collection of peripheral blood at each time point; 5. Patients have signed the informed consent form, or the broad informed consent form, or meet the criteria for exemption from informed consent; 6. Patients can attend scheduled follow-ups, communicate well with researchers, and complete the study in accordance with the requirements.
Exclusion criteria
Exclusion criteria: 1. Patients with a history of other malignant tumors are not allowed to participate in the study, unless they have achieved complete remission for at least 5 years before enrollment and do not require additional treatment, or will not need to receive other treatments during the study period; 2. Patients with severe anemia; 3. Incomplete information about the subjects; 4. Pregnant, planning to become pregnant, or lactating women; 5. Subjects with a history of severe mental illness; 6. Patients who received blood transfusion two weeks before surgical resection or during the surgery; 7. Patients with any other conditions that, in the investigator’s opinion, may interfere with the assessment of the subjects.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence-Free Survival(RFS);Recurrence Rate in MRD+; | — |
Secondary
| Measure | Time frame |
|---|---|
| The interval between the occurrence time of MRD positivity and the recurrence time;Sensitivity and specificity of MRD in predicting recurrence;Consistency between MRD and traditional monitoring methods;MRD Clearance Rate;MRD in each subgroup predicts the efficacy of recurrence and metastasis; | — |
Countries
China
Contacts
Public ContactWei Bing; Sun Haibo
HenanCancerHospital
Outcome results
None listed